Floatz logo

Olaparib

Ovarian Serous Surface Papillary Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Ovarian Serous Surface Papillary Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2B
Everolimus
Mayo Clinic
Phase 2B
Letrozole
Mayo Clinic
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
AZD1775
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →